NASDAQ:AEMD Aethlon Medical Q4 2026 Earnings Report $2.14 -0.27 (-11.00%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aethlon Medical EPS ResultsActual EPSN/AConsensus EPS -$2.17Beat/MissN/AOne Year Ago EPSN/AAethlon Medical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAethlon Medical Announcement DetailsQuarterQ4 2026Date6/25/2026TimeAfter Market ClosesConference Call DateFriday, June 26, 2026Conference Call Time4:15PM ETConference Call ResourcesEarnings HistoryCompany Profile Aethlon Medical Earnings HeadlinesAethlon Medical (NASDAQ:AEMD) Share Price Crosses Above 200 Day Moving Average - What's Next?May 30 at 2:23 AM | americanbankingnews.comAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic PreparednessMay 21, 2026 | prnewswire.com"You'll own nothing and be happy" (it's not a theory anymore)Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.June 2 at 1:00 AM | Decentralized Masters (Ad)AEMD: Hitting key milestones as company advances clinical studyMarch 24, 2026 | msn.comAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB ReviewMarch 24, 2026 | prnewswire.comOTC Markets Hosts Virtual Investor Presentation with Jim Frakes, CEO and CFO of Aethlon Medical, and M. Marin, Senior Analyst at Zacks SCRMarch 20, 2026 | msn.comSee More Aethlon Medical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aethlon Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aethlon Medical and other key companies, straight to your email. Email Address About Aethlon MedicalAethlon Medical (NASDAQ:AEMD) (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings. The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components. Aethlon has advanced the device through human clinical trials, exploring its potential in patients with viral infections—such as hepatitis C and COVID-19—and in oncology patients where tumor‐derived exosomes contribute to immune system evasion. The company continues to refine its technology, pursue regulatory designations, and seek strategic collaborations to expand its clinical development efforts. Headquartered in San Diego, California, Aethlon Medical was established with a mission to bring innovative extracorporeal therapies to market. Under the leadership of President and Chief Executive Officer Phillip D. Borden, the company engages with regulatory agencies and research institutions across North America and internationally. Aethlon’s research and development operations are complemented by partnerships aimed at accelerating the clinical evaluation of its platform and ultimately delivering new treatment options for patients with urgent medical needs.View Aethlon Medical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointHubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?5 Reasons to Pony Up for Pony AI Stock—and 1 Reason to WaitBraze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceDrone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name Upcoming Earnings Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
